Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: A white paper

Drug Metabolism and Disposition

Volumn 41, Issue 9, 2013, Pages 1598-1609

  Evers, Raymond ^a   Dallas, Shannon ^b   Dickmann, Leslie J ^c   Fahmi, Odette A ^d   Kenny, Jane R ^e   Kraynov, Eugenia ^f   Nguyen, Theresa ^a   Patel, Aarti H ^g   Slatter, J Greg ^c   Zhang, Lei ^h  

^a MERCK RESEARCH LABORATORIES   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c AMGEN INC   (United States)

^d Dynamics and Metabolism   (United States)

^e GENENTECH INC   (United States)

^f PFIZER INC   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OMEPRAZOLE; PREGNANE X RECEPTOR; RETINOID X RECEPTOR ALPHA; SIMVASTATIN; SMALL MOLECULE TRANSPORT AGENT; TOCILIZUMAB;

CYTOKINE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG PROTEIN BINDING; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CULTURE; LIVER FUNCTION; MOLECULAR MODEL; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; SIMULATION;

QUERCUS ALBA;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84882779915     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052225     Document Type: Review

References (65)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, and Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715.
2. Aitken AE and Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35: 1687-1693.
3. Aitken AE, Richardson TA, and Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
4. Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, and Yoshida T (2007) Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur J Pharmacol 558:199-207.
5. Bader A, Borel Rinkes IH, Closs EI, Ryan CM, Toner M, Cunningham JM, Tompkins RG, and Yarmush ML (1992) A stable long-Term hepatocyte culture system for studies of physiologic processes: cytokine stimulation of the acute phase response in rat and human hepatocytes. Biotechnol Prog 8:219-225.
6. Chen C, Han YH, Yang Z, and Rodrigues AD (2011) Effect of interferon-A2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Xenobiotica 41:476-485.
7. Dallas S, Chattopadhyay S, Sensenhauser C, Batheja A, Singer M, and Silva J (2013a) Interleukins-12 and -23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes. Drug Metab Dispos 41:689-693.
8. Dallas S, Sensenhauser C, Batheja A, Singer M, Markowska M, Zakszewski C, Mamidi RN, McMillia M, Han C, and Zhou H, et al. (2012) De-risking bio-Therapeutics for possible drug interactions using cryopreserved human hepatocytes. Curr Drug Metab 13:923-929.
9. Dallas S, Sensenhauser S, Chattopadhyay C, and Silva J (2013b) Drug Interaction Assessment Strategies: Small Molecules versus Therapeutic Proteins, in Drug-Drug Interactions for Therapeutic Proteins, Chap 3, Wiley, New York, 39-62.
10. Deng R, Jin F, Prabhu S, and Iyer S (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8:141-160.
11. Diao L, Li N, Brayman TG, Hotz KJ, and Lai Y (2010) Regulation of MRP2/ABCC2 and BSEP/ ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-Alpha, IL-6, and IL-1beta. J Biol Chem 285:31185-31192.
12. Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, and Slatter JG (2012b) Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. Biochem Pharmacol 83:1682-1689.
13. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, and Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415-1422.
14. Dickmann LJ, Patel SK, Wienkers LC, and Slatter JG (2012a) Effects of interleukin 1b (IL-1b) and IL-1b/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab 13:930-937.
15. Donato MT, Guillén MI, Jover R, Castell JV, and Gómez-Lechón MJ (1997) Nitric oxidemediated inhibition of cytochrome P450 by interferon-g in human hepatocytes. J Pharmacol Exp Ther 281:484-490.
16. Donato MT, Herrero E, Gómez-Lechón MJ, and Castell JV (1993) Inhibition of monooxygenase activities in human hepatocytes by interferons. Toxicol In Vitro 7:481-485.
17. Fardel O and Le Vée M (2009) Regulation of human hepatic drug transporter expression by proinflammatory cytokines. Expert Opin Drug Metab Toxicol 5:1469-1481.
18. Ferrari L, Peng N, Halpert JR, and Morgan ET (2001) Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol Pharmacol 60:209-216.
19. Freudenberg MA, Freudenberg N, and Galanos C (1982) Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. Br J Exp Pathol 63:56-65.
20. Ghose R, Zimmerman TL, Thevananther S, and Karpen SJ (2004) Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2:4.
21. Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, Evers R, Zhou H, Zhu M, and Klunk L, et al. (2011) AAPS workshop report: strategies to address therapeutic proteindrug interactions during clinical development. AAPS J 13:405-416.
22. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, and Tian Y (2006) Role of NFkappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 281:17882-17889.
23. Guillén MI, Donato MT, Jover R, Castell JV, Fabra R, Trullenque R, and Gómez-Lechón MJ (1998) Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J Pharmacol Exp Ther 285:127-134.
24. Hartmann G, Vassileva V, and Piquette-Miller M (2005) Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33: 820-828.
25. Hartz AM, Bauer B, Fricker G, and Miller DS (2006) Rapid modulation of P-glycoproteinmediated transport at the blood-brain barrier by tumor necrosis factor-Alpha and lipopolysaccharide. Mol Pharmacol 69:462-470.
26. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, and Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
27. Hoebe KH, Witkamp RF, Fink-Gremmels J, Van Miert AS, and Monshouwer M (2001) Direct cell-To-cell contact between Kupffer cells and hepatocytes augments endotoxin-induced hepatic injury. Am J Physiol Gastrointest Liver Physiol 280:G720-G728.
28. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, and Lesko LJ (2010) Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 87: 497-503.
29. Jover R, Moya M, and Gómez-Lechón MJ (2009) Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-Alpha. Curr Drug Metab 10:508-519.
30. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, and Piquette-Miller M (2004) Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-Treated rats. Drug Metab Dispos 32:20-27.
31. Kenny J, Liu MM, Chow AT, Earp JC, Evers R, Slatter JG, Wang DD, Zhang L, and Zhou H (2013) Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop. AAPS J DOI: 10.1208/s12248-013-9495-1 [published ahead of print].
32. Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, Loi CM, Kuang B, Fields O, and Fountain S, et al. (2011) How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential. Drug Metab Dispos 39:1779-1783.
33. Lee CM, Pohl J, and Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 37: 865-872.
34. Lee JI, Zhang L, Men AY, Kenna LA, and Huang SM (2010) CYP-mediated therapeutic proteindrug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 49:295-310.
35. Le Vee M, Jouan E, Stieger B, Lecureur V, and Fardel O (2011) Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochem Pharmacol 82:304-311.
36. Le Vee ML, Lecureur V, Stieger B, and Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-A or interleukin-6. Drug Metab Dispos 37:685-693.
37. Ling S and Jamali F (2009) The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-Adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin Pharmacol Toxicol 105:24-29.
38. Lloyd P, Zhou H, Theil FP, Kakkar T, Nestorov I, and Roberts SA; Pharmacokinetics and Disposition Expert Working Group Drug-Drug Interaction Taskforce (2012) Highlights from a recent BIO survey on therapeutic protein-drug interactions. J Clin Pharmacol 52:1755-1763.
39. Lobo ED, Hansen RJ, and Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
40. Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, and Kenny JR (2013) A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease-Drug Interactions: Suppression of CYP3A by IL-6. Clin Pharmacol Ther DOI: 10.1038/clpt.2013.79 [published ahead of print].
41. Mahmood I and Green MD (2007) Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 47:1540-1554.
42. Matsumoto J, Dohgu S, Takata F, Nishioku T, Sumi N, Machida T, Takahashi H, Yamauchi A, and Kataoka Y (2012) Lipopolysaccharide-Activated microglia lower P-glycoprotein function in brain microvascular endothelial cells. Neurosci Lett 524:45-48.
43. Morgan ET (2001) Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207-212.
44. Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438.
45. Morgan ET, Li-Masters T, and Cheng PY (2002) Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 181-182:207-210.
46. Muntané-Relat J, Ourlin JC, Domergue J, and Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153.
47. Nguyen T, Kishnani N, and Evers R (2013) Utility of in vitro methods in drug-drug interaction assessments and prediction for therapeutic biologics, in Drug interactions of therapeutic proteins, (Meibohm B and Zhou H eds) pp 73-102, Wiley, New York.
48. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, and Vilarem MJ (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274:707-713.
49. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111.
50. Piquette-Miller M and Jamali F (1995) Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-Treated and untreated adjuvant arthritis. Drug Metab Dispos 23:240-245.
51. Schmitt C, Kuhn B, Zhang X, Kivitz A, and Grange S (2012) Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 50:218-223.
52. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, and Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89:735-740.
53. Seitz K and Zhou H (2007) Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 47:1104-1118.
54. Sifontis NM, Benedetti E, and Vasquez EM (2002) Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 34:1730-1732.
55. Slatter JG, Wienkers LC, and Dickmann LJ (2013) Drug interactions of cytokines and anticytokine therapeutic proteins, in Drug interactions of therapeutic proteins, chap 13 (Meibohm B and Zhou H eds) Wiley, New York. 215-238.
56. Strehlau J, Pape L, Offner G, Nashan B, and Ehrich JH (2000) Interleukin-2 receptor antibodyinduced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 356:1327-1328.
57. Sunman JA, Hawke RL, LeCluyse EL, and Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359-363.
58. Vasquez EM and Pollak R (1997) OKT3 therapy increases cyclosporine blood levels. Clin Transplant 11:38-41.
59. Wang JH, Scollard DA, Teng S, Reilly RM, and Piquette-Miller M (2005) Detection of Pglycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl Med 46: 1537-1545.
60. Yang KH and Lee MG (2008) Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs. Arch Pharm Res 31:1073-1086.
61. Zhang X, Schmitt C, Grange S, Terao K, Miya K, Kivitz A, and Marino M (2009) Disease-Drug Interaction studies of Tocilizumab with cytochrome P450 substrates in vitro and in vivo. Clin Pharmacol Ther 85 (Supplement 1):S37-S64 Abstract PII-73.
62. Zhao H, Zhang L, Reynolds KS, and Huang S-M (2013) FDA Perspectives on Therapeutic Protein Drug-Drug Interaction Assessments, in Drug-Drug Interactions for Therapeutic Proteins pp 155-190, Wiley, New York.
63. Zhou C, Verma S, and Blumberg B (2009) The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 7:e001.
64. Zhou H and Mascelli MA (2011) Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol 51:359-372.
65. Zordoky BN and El-Kadi AO (2009) Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab 10:164-178.